NYSE: HAE

Haemonetics Corp. (HAE)

Haemonetics Corp. is a public company that reports to the U.S. Securities and Exchange Commission and trades on NYSE under the ticker HAE. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
HAE
Exchange
NYSE
SEC CIK
313143
Official filings
SEC EDGAR

Research HAE

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Haemonetics Corp.'s stock ticker?

Haemonetics Corp. trades under the ticker symbol HAE on NYSE. Its SEC Central Index Key (CIK) is 313143.

Where can I read Haemonetics Corp.'s SEC filings?

The HAE SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Haemonetics Corp. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze HAE's financial statements?

The HAE Financials page shows Haemonetics Corp.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does HAE compare with its peers and the market?

The HAE Peer Comparison page lines Haemonetics Corp. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.